InvestSMART

AVITA Medical, Inc. (ASX:AVH)

ALERT: Price-sensitive ASX Announcement for AVH
Current share price for AVH : $1.365 0.165 (13.75%)+
Announcement
Release
15 May 2026 8:23AM
Price at Release
$1.200
Full Release
download
Summary
AVITA Medical, Inc. reported financial results for the quarter ending March 31, 2026, with a net loss of $10.6 million, an improvement from the previous year's loss. Revenues rose to $19.25 million, driven by commercial sales, while operating expenses decreased due to reduced sales and marketing costs. The company managed total assets of $51.5 million, including cash equivalents and marketable securities, balancing against liabilities of $74.7 million. Despite the losses, AVITA continued to invest in its RECELL product line and maintained a strong presence in the U.S. market.
Key Points
  • AVITA Medical, Inc. reported a net loss of $10.6 million for the quarter ending March 31, 2026, compared to a loss of $13.9 million in the previous year.
  • The company’s total revenue increased to $19.25 million from $18.51 million in the prior year, with significant contributions from commercial sales.
  • Operating expenses decreased from $27.5 million to $24.5 million, driven by reductions in sales and marketing expenses.
  • The company recorded comprehensive losses of $8.6 million, down from $12.3 million the previous year, partly due to changes in the fair value of financial instruments.
  • AVITA’s cash and cash equivalents totaled $8.3 million as of March 31, 2026, with an additional $6 million in marketable securities.
  • The company has liabilities of $74.7 million, including a loan facility valued at $46.1 million and warrant liabilities of $2.2 million.
  • AVITA issued 144,895 shares of common stock due to the exercise of penny warrants and recorded stock-based compensation of $1.1 million.
  • The company operates primarily in the United States, with substantial revenue generated from its RECELL product line.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.